2024 - Medicare Part D price negotiation update

The Inflation Reduction Act and the resulting Medicare Part D price negotiations are shaping up to be the most far reaching of any event impacting pharma manufacturing in recent history.
Although the first set of negotiated prices for selected drugs will not take effect until January 1, 2026, the immediate impact has been fast and furious — a total of nine lawsuits have been filed by pharmaceutical companies, advocacy groups and the US Chamber of Commerce. Industry media is ablaze with discussions on how price negotiations will impact the pricing of non-selected same-class drugs and biosimilars as well as future drug development in general.
Now that the first-round negotiated prices for selected drugs will be made public on September 1, 2024, and companies prepare themselves for the second round of selections, this timely webinar will provide an update on:
To-date information on the legal actions, existing price negotiations and market reactions
Drugs likely to be selected for the second round and their same-class competitors who will be impacted
How manufacturers should prepare for the overall impact to the industry
Register for this webinar today to understand the profound impact of the Inflation Reduction Act and Medicare Part D price negotiations on the pharmaceutical industry.
Keywords: Pharmaceutical, Drug Development, Pharmaceutical Manufacturing, Medicare, Biosimilars, Regulatory, Regulatory Affairs, Marketing, Commercial Manufacturing, Commercialization/HEOR/Market Access, Drug Prices